Amid a current Ebola outbreak in the Congo and surrounding regions, a global coalition is accelerating the development and evaluation of three vaccine candidates. With dedicated funding and international collaboration, these initiatives aim to address critical gaps in outbreak control through effective vaccines.
Amid a current Ebola outbreak in the Congo and surrounding regions, a global coalition is accelerating the development and evaluation of three vaccine candidates. With dedicated funding and international collaboration, these initiatives aim to address critical gaps in outbreak control through effective vaccines.
READ MORE
Medicare's ongoing refusal to disclose the financial implications of providing GLP-1 obesity drugs to seniors has sparked scrutiny, with Massachusetts initiating legal action against United Healthcare amid broader healthcare coverage debates.
The FDA's failure to meet its self-imposed deadline to ban electrical shock devices in individuals with intellectual disabilities has drawn significant criticism from disability rights groups and advocates.
French pharmaceutical company Servier has agreed to acquire an experimental muscular dystrophy drug from Edgewise Therapeutics in a deal valued at $1.55 billion upfront.
Regeneron Pharmaceuticals' multiple myeloma drug linvoseltamab has demonstrated extraordinary clinical trial results in patients with the rare blood disease light chain amyloidosis, signaling a potential breakthrough in treatment.
Emerging evidence reveals a critical link between oral health and pregnancy outcomes, emphasizing the role of care providers, states, and insurance plans in prioritizing dental care.
Signos has secured $20 million in funding to broaden its glucose monitoring platform's use, aiming to leverage CGM technology beyond diabetes management into weight loss and lifestyle optimization.
May 2026 witnessed significant funding rounds in health technology, underscoring continued investor confidence and accelerating innovation in digital health solutions.
Emerging evidence suggests that ultra-low doses of costly cancer immunotherapies may dramatically increase treatment accessibility in poorer nations without compromising efficacy.
Recent findings presented at ASCO 2026 reveal that daraxonrasib, a novel drug targeting pancreatic cancer, effectively inhibits a challenging molecular target, offering new hope for treatment of this aggressive disease.
A recent study presented at ASCO 2026 indicates that administering hormone therapy before surgery in prostate cancer patients can significantly reduce relapse rates, suggesting a potential shift in treatment protocols.
